/

ACRS

Aclaris Therapeutics, Inc.Closed

3.47−0.13 −3.61%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 3.39 −2.42%

Open

3.65

Prev close

3.60

Day range

3.413.65

52-week range

1.746.60

Volume

3.44M1.28×

Mkt cap

510.78M

P/E ttm

—

Fwd P/E

-4.41

EPS ttm

-0.5800

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−47.42%

Price Chart

Yahoo Finance · delayed

ACRSOct 12, 2026O 3.80H 3.84L 3.59C 3.60−0.23 (−6.01%)Vol 3.43M

SMA 505.53
SMA 2004.47

1Y change +92.51% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ACRS Aclaris Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −15.69%
1 month: −32.33%
3 months: −34.55%
6 months: −7.69%
Year to date: +19.60%
1 year: +92.51%

Valuation & ownership

Market cap: 510.78M
Enterprise value: 421.07M
P/E (ttm): —
Forward P/E: -4.41
PEG ratio: —
Price / book: 3.89
Price / sales (ttm): 62.15
EV / EBITDA: -4.92
EPS (ttm): -0.5800
EPS (forward): -0.7873
Beta (5y monthly): 0.88
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 147.20M
Float: 101.17M
Short % of float: 14.03%
Short ratio (days): 6.83
Held by insiders: 2.18%
Held by institutions: 84.00%
Avg volume (3m): 2.68M
50-day average: 5.53
200-day average: 4.47
52-week change: +92.51%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 29.5
vs 50-day SMA: −34.88%
vs 200-day SMA: −19.47%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 10.88%
Realised vol (20d, ann.): 104.0%
From 52-week high: −45.45%
From 52-week low: +106.90%

ANR

Analyst Consensus

11 analysts

Consensus

Strong buy

1.25 on a 1 (strong buy) – 5 (sell) scale

Mean target

10.18

+193.42% implied

Low 4.00Median 10.00High 16.00

Recommendation trend

Now11 / 1 / 0
1m ago / 1 /

DES

About Aclaris Therapeutics, Inc.

Yahoo Finance profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Sector: Healthcare
Industry: Biotechnology
Employees: 69
Headquarters: Wayne, PA, United States
Website: aclaristx.com
Officers: Dr. Neal S. Walker D.O., M.D. Co-Founder, CEO & Chairman
Dr. Hugh M. Davis Ph.D. President, COO & Director

SEAS

Seasonality · ACRS

2015–2026 · monthly returns

Strongest month Jan +14.35%Weakest month Mar −5.48%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	16.6	-18.2	30.7	15.7	4.8	16.3	-1.7	16.3	-13.1	-34.0			+15.3%
2025	0.0	-19.8	-23.1	-9.8	5.8	-2.7	7.7	26.1	-1.6	32.6	12.3	6.4	+21.4%
2024	10.5	2.6	4.2	-2.4	-14.9	6.8	21.8	-11.9	-2.5	57.4	124.9	-39.1	+136.2%
2023	7.3	-26.3	-35.1	9.9	-6.1	24.2	-4.8	-24.2	-8.4	-27.3	-82.4	20.0	−93.3%
2022	-24.9	36.4	15.7	-28.5	3.8	9.1	10.4	3.2	-1.1	-0.8	-2.5	3.5	+8.3%
2021	220.7	7.4	13.1	-5.4	-6.8	-21.0	-15.0	8.6	11.0	-3.6	-26.2	13.6	+124.7%
2020	-34.4	-8.1	-8.8	27.9	6.0	14.9	32.7	14.4	4.5	49.4	-13.0	93.7	+242.3%
2019	-5.7	-7.0	-7.6	5.2	-25.7	-53.2	-41.6	-21.1	6.9	62.0	-6.3	15.2	−74.4%
2018	-10.3	-9.9	-12.1	1.3	1.8	10.5	-14.2	-7.1	-8.8	-18.1	-21.6	-20.7	−70.0%
2017	-2.2	17.7	-4.5	-5.7	-15.4	14.0	6.2	-10.0	-0.5	-2.3	-6.0	4.0	−9.1%
2016	-17.5	-17.5	3.3	-2.5	8.1	-7.6	6.7	2.3	27.0	-17.0	40.9	-9.4	+0.7%
2015											62.8	14.4	+86.2%

INSD

Insider Activity · ACRS

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

142.2K shares

Sells, 6 months

300K shares

Net shares

−157.8K

Net change in insider shares

−4.70%

Date	Insider	Transaction	Shares	Value
Jul 30, 2026	Kolbeck Roland WilhelmOfficer	—	36.4K	—
Jun 4, 2026	Molineaux Christopher PDirector	—	11.6K	—
Jun 4, 2026	Humphries William DouglasDirector	—	11.6K	—
Jun 4, 2026	Milano Vincent JDirector	—	11.6K	—
Jun 4, 2026	Schiff Andrew NDirector	—	11.6K	—
Jun 4, 2026	Gowen MaxineDirector	—	11.6K	—
Jun 4, 2026	Mehra Anand M.D.Director	—	11.6K	—
Apr 30, 2026	Hall Jesse Wayne M.D.Officer	—	36.4K	—
Apr 22, 2026	Leonard Braden MichaelBeneficial Owner of more than 10% of a Class of Security	Sale at price 4.53 per share.	300K	$1.36M
Feb 26, 2026	Balthaser Kevin JChief Financial Officer	—	2.4K	—
Feb 2, 2026	Walker NealChief Executive Officer	—	63.5K	—
Feb 2, 2026	Loerop JamesOfficer	—	20.9K	—
Feb 2, 2026	Balthaser Kevin JChief Financial Officer	—	22K	—
Feb 2, 2026	Davis Hugh M.President	—	18.7K	—
Jan 29, 2026	Loerop JamesOfficer	—	33.5K	—
Jan 29, 2026	Balthaser Kevin JChief Financial Officer	—	14.8K	—
Jan 1, 2026	Walker NealChief Executive Officer	—	29.1K	—
Jan 1, 2026	Loerop JamesOfficer	—	91.9K	—
Jan 1, 2026	Balthaser Kevin JChief Financial Officer	—	94.5K	—
Dec 1, 2025	Davis Hugh M.President	—	26.8K	—

13F

Investors Holding ACRS

latest 13F filings of 29 followed managers

Investors holding ACRS
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$4.3M	0.01%	817.53K	+63%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ACRS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ACRS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Aclaris Therapeutics, Inc.

Seasonality · ACRS

Insider Activity · ACRS

Congress Trades · ACRS

Investors Holding ACRS

Investors Holding ACRS

Congress Trades · ACRS

Insider Activity · ACRS

Seasonality · ACRS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Aclaris Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News